PBYI logo

Puma Biotechnology, Inc.

PBYI
Healthcare|Biotechnology|US
$8.25
-1.52 (-15.56%)
DCF Value
$16.32
Tangible Book / Share
$2.10
Cash / Share
$2.10
Next Earnings Report
Feb 25, 2027
EPS est. $0.23 · Revenue est. $67.2M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (8)

Dec 2026
Est. completion
P2Breast Cancer
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT04886531n=30
Jun 2027
Est. completion
P1Gastric Cancer
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
NCT05274048n=18
Oct 2027
Est. completion
P2Small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505n=120
Dec 2027
Est. completion
P2Hormone Receptor Positive HER-2 Negative Breast Cancer
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285n=225
Feb 2028
Est. completion
P2Glioblastoma
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780n=460
Mar 2028
Est. completion
P2GastroEsophageal Cancer
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
NCT06109467n=8
Mar 2028
Est. completion
P2Small Cell Lung Cancer ( SCLC )
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757n=50
Apr 2030
Est. completion
P2Anatomic Stage I Breast Cancer
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108n=30

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2024
P1
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
NCT04502602
Oct 2024
P2
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
NCT05252988

Recent Press Releases

Puma Biotechnology Reports Third Quarter 2026 Financial Results
Nov 5, 2026 · Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2026 · Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Oct 22, 2026 · Business Wire
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2026 · Business Wire
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Sep 17, 2026 · Business Wire
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Sep 9, 2026 · Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2026 · Business Wire

SEC Filings (35)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 6, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 7, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Nov 6, 202510-QQuarterly reportDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Aug 7, 202510-QQuarterly reportDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Aug 7, 202510-Q/AQuarterly reportDocumentIndex
Jun 24, 20258-KMaterial eventDocumentIndex
Jun 13, 20258-KMaterial eventDocumentIndex
May 9, 20258-KMaterial eventDocumentIndex
May 8, 202510-QQuarterly reportDocumentIndex
May 8, 20258-KMaterial eventDocumentIndex
Apr 28, 2025DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2025ARSAnnual report to holdersDocumentIndex
Apr 28, 2025DEF 14AProxy / shareholder voteDocumentIndex
Apr 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Feb 27, 202510-KAnnual reportDocumentIndex
Feb 27, 20258-KMaterial eventDocumentIndex
Feb 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Feb 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Feb 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2024SC 13G/APassive 5%+ stakeDocumentIndex